{"id":949602,"date":"2026-04-07T16:06:01","date_gmt":"2026-04-07T20:06:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/goss-investor-alert-gossamer-bio-securities-fraud-lawsuit-investors-with-losses-may-seek-to-lead-the-class-action-after-company-allegedly-overstated-trial-prospects-levi-korsinsky\/"},"modified":"2026-04-07T16:06:01","modified_gmt":"2026-04-07T20:06:01","slug":"goss-investor-alert-gossamer-bio-securities-fraud-lawsuit-investors-with-losses-may-seek-to-lead-the-class-action-after-company-allegedly-overstated-trial-prospects-levi-korsinsky","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/goss-investor-alert-gossamer-bio-securities-fraud-lawsuit-investors-with-losses-may-seek-to-lead-the-class-action-after-company-allegedly-overstated-trial-prospects-levi-korsinsky\/","title":{"rendered":"GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Trial Prospects: Levi & Korsinsky"},"content":{"rendered":"

<\/p>\n

GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Trial Prospects: Levi & Korsinsky<\/p>\n

Promise vs. Reality: The Gossamer Bio PROSERA Performance Gap<\/i><\/p>\n

NEW YORK–(BUSINESS WIRE<\/a>)–“We firmly believe that we have accomplished this patient selection goal.” That was the promise. The reality: a Phase 3 trial that failed its primary endpoint, and shareholders who lost over 80% of their investment in a single trading session.<\/p>\n

Levi & Korsinsky, LLP notifies investors in Gossamer Bio, Inc. (NASDAQ: GOSS) that a securities class action has been filed on behalf of purchasers who acquired GOSS stock between June 16, 2025 and February 20, 2026. Find out if you can recover your GOSS investment losses<\/a> or contact Joseph E. Levi, Esq. at\u00a0jlevi@levikorsinsky.com<\/a> or (212) 363-7500.<\/p>\n

Shares collapsed from $2.13 to $0.42, a loss of $1.71 per share (over 80%), after Gossamer disclosed that its Phase 3 PROSERA study for seralutinib in pulmonary arterial hypertension failed to meet the prespecified statistical threshold.<\/p>\n

The Promise<\/b><\/p>\n

Throughout the Class Period, the company projected confidence that PROSERA was on track. Management told investors the trial had enrolled a patient population “that aligns closely with the study’s objectives” and was “more likely to exhibit a clinically significant benefit in 24 weeks,” drawing on “insights from the Phase 2 TORREY Study.” The company further assured investors it was “executing the PROSERA Study with discipline and operational excellence.”<\/p>\n

The Reality<\/b><\/p>\n

On February 23, 2026, Gossamer revealed that the study produced only a +13.3 meter placebo-adjusted improvement in six-minute walk distance with a p-value of 0.0320, failing the prespecified 0.025 alpha threshold. The miss was attributed to an outsized placebo response at Latin American clinical sites, where heavily-treated, lower-risk patients performed unexpectedly well on placebo, including “super responders” with over 100-meter walk improvements on placebo alone.<\/p>\n

The Numbers: Promised vs. Actual<\/b><\/p>\n